Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (194)	7/10/2001 4:40:23 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 1022

From collaboration in 1999 to entering clinical development 2001. That's cool. Abgenix Reaches Milestone in Antibody Collaboration With Amgen Fully Human Antibody Generated with Abgenix's Technology in Clinical Trials FREMONT, Calif.--(BUSINESS WIRE)--July 10, 2001--Abgenix, Inc. (NASDAQ: ABGX - news) today announced that Amgen Inc. (Amgen) has advanced into clinical trials a fully human antibody generated with Abgenix's technology. This milestone triggers an undisclosed payment to Abgenix. ``We are pleased with the productivity of our collaboration with Amgen, which has resulted in the rapid advancement of this product candidate. Four fully human antibodies derived from Abgenix technology are in human clinical trials, including two of our own,'' said R. Scott Greer, chairman and chief executive officer of Abgenix. ``We believe our fully human antibody platform will continue to provide new and important antibody therapies for various diseases.'' Abgenix's research collaboration with Amgen began in April 1999 for Abgenix to use its technology to generate fully human monoclonal antibody candidates to undisclosed antigen targets supplied by Amgen during the five-year term of the alliance.